PDCD1 and neoplasm: Immune checkpoint inhibitors (ICIs) reduce immunosuppression in the tumor microenvironment and reactivate the anti-tumor function of T cells by inhibiting cytotoxic T lymphocyte-associated protein 4 and programmed cell death-1 pathway/programmed cell death receptor ligand-1 (PD-L1) (Kang et al., 2021).